pharma · Chronic Spontaneous Urticaria · Asthma
Novartis India
Novartis Pharmaceuticals
Novartis Pharmaceuticals is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Spontaneous Urticaria, Asthma, Systemic Lupus Erythematosus, Breast Cancer, Multiple Sclerosis. NovaP
Mumbai, IN HQ
1996 Founded
2,240 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Mumbai, IN
- Founded
- 1996
- Employees
- 2,240
- Programs
- 341
- Drugs
- 317
- Patents
- 0
DYP688
Phase 2 · small molecule · Metastatic uveal melanoma, other GNAQ/11 mutant melanomas (e.g. skin or mucosal melanoma)
DYP688 for Metastatic uveal melanoma, other GNAQ/11 mutant melanomas (e.g. skin or mucosal melanoma) is a Phase 2 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code CDYP688A12101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Metastatic uveal melanoma, other GNAQ/11 mutant melanomas (e.g. skin or mucosal melanoma)
- Status
- active
- Trials
- 1